Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...

Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...

Investing.com -- HUTCHMED (NASDAQ:HCM) stock gained 1.9% in premarket trading Wednesday after the company announced that its Phase III trial of sovleplenib in patients with warm antibody autoimmune ...

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing ...

The Hong Kong-based developer of treatments for cancer and immunological diseases said the trial in adults with warm antibody autoimmune hemolytic anaemia [wAIHA] in China met its primary endpoint of ...

Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHME ...

Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...

In addition to wAIHA, sovleplenib is also being studied in immune thrombocytopenia (“ITP”). Positive results from ESLIM-01 ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

Agios Pharmaceuticals AGIO announced that the FDA has approved Aqvesme (mitapivat) for the treatment of adult patients with ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

Anemia can cause fatigue, weakness, and pale or yellow skin. Severe anemia can lead to serious symptoms like shortness of breath and fast heartbeat. Iron deficiency anemia may cause cold hands and ...